U.S., Jan. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07339345) titled 'Prospective Single-Arm Clinical Trial of GO Regimen for HLH.' on Jan. 01.
Brief Summary: This study aims to investigate the efficacy and safety of Golidocitinib(GO) monotherapy in the treatment of hemophagocytic lymphohistiocytosis.
Study Start Date: June 27, 2025
Study Type: INTERVENTIONAL
Condition:
Lymphohistiocytosis, Hemophagocytic
Intervention:
DRUG: Golidocitinib
Administer the GO regimen to HLH patients who meet the inclusion criteria, specifically Golicitinib 150 mg once daily.
Recruitment Status: RECRUITING
Sponsor: Beijing Friendship Hospital
Information provided by (Responsible Party): Zhao Wang, Beijing Friend...